Clinical Trial Detail

NCT ID NCT02561832
Title A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide

Olaparib

Carboplatin

Age Groups: adult

Additional content available in CKB BOOST